Permanent Advert Space and content sponsorship Available. Contact Admin:- sappertekinc@gmail.com, admin@ubuntusafa.com

Tuesday, November 17, 2026

THE GLOBAL PHARMACEUTICAL WAR: Who Will Control the Medicines, Vaccines and Biotechnology of the 21st Century?

 


THE GLOBAL PHARMACEUTICAL WAR: Who Will Control the Medicines, Vaccines and Biotechnology of the 21st Century?

The next great contest for global power may not be fought over oil, gas or semiconductors alone. It may be fought over the medicines that keep populations alive, the vaccines that protect nations, the biotechnology that treats previously incurable diseases and the manufacturing systems that determine who gets access to them.

A country can have advanced hospitals, world-class doctors and sophisticated medical technology. But if it cannot reliably obtain essential medicines, vaccines, pharmaceutical ingredients and specialised treatments, its healthcare system remains strategically vulnerable.

The COVID-19 pandemic exposed this vulnerability.

Countries competed for vaccines, restricted exports, secured manufacturing contracts and discovered that pharmaceutical supply chains were more concentrated than many governments had realised.

The crisis revealed a fundamental truth: the ability to discover medicines is important, but the ability to manufacture them reliably, at scale and at affordable prices is also a form of national power.

Today, the pharmaceutical industry is entering another transformation. Artificial intelligence is accelerating drug discovery. Biotechnology is creating new classes of treatment. China is expanding its research and manufacturing capabilities. India remains a major supplier of generic medicines. The United States and Europe retain substantial pharmaceutical research and intellectual-property strengths. Japan and South Korea are expanding their biotechnology capabilities.

And Africa is beginning to confront a strategic question of its own: how can a continent that imports a substantial proportion of its medicines develop the capacity to manufacture more of what its people need?

This is not simply a competition between pharmaceutical companies.

It is a contest involving science, capital, intellectual property, industrial capacity, public health, international trade and geopolitical influence.

The Pharmaceutical Industry Is Becoming a Strategic Industry

For much of the late 20th century, pharmaceutical competition was understood primarily as a contest between large companies developing new medicines and selling them in international markets.

That model is changing.

Governments increasingly recognise that medicines are essential infrastructure. A country that cannot secure antibiotics, insulin, vaccines, cancer treatments or the chemical ingredients needed to manufacture them faces risks extending beyond healthcare.

The pharmaceutical industry now has several interconnected layers:

  1. Scientific discovery: identifying new medicines and biological targets.

  2. Clinical development: testing whether treatments are safe and effective.

  3. Intellectual property: controlling patents, licences and commercial rights.

  4. Active pharmaceutical ingredients: manufacturing the substances that make medicines work.

  5. Finished-dose manufacturing: producing tablets, capsules, injections and other formulations.

  6. Biotechnology manufacturing: producing complex biological medicines and vaccines.

  7. Regulatory approval: demonstrating quality, safety and efficacy.

  8. Distribution and procurement: ensuring that products reach patients reliably and affordably.

Control of one layer does not mean control of the entire industry.

A country might discover a breakthrough cancer medicine but depend on foreign manufacturers to produce it. Another might manufacture millions of generic tablets but have limited capacity to discover new treatments.

The most influential pharmaceutical economies will increasingly be those that can connect research, intellectual property, manufacturing, regulation and international distribution.

The Global Supply Chain: Who Makes the Medicines the World Depends On?






One of the most important lessons of the COVID-19 pandemic was that pharmaceutical supply chains are international, interconnected and sometimes highly concentrated.

A medicine may be designed in America, developed using research from Europe, manufactured using chemical ingredients from China, formulated in India and distributed across Africa or Asia.

This global division of labour can reduce costs and increase efficiency.

But it can also create vulnerabilities.

Consider active pharmaceutical ingredients, commonly known as APIs.

An API is the substance in a medicine responsible for its therapeutic effect. Without it, a manufacturer cannot produce the finished medicine.

The upstream supply chain also depends on key starting materials and chemical intermediates.

A factory in India or Europe may manufacture the final API but still depend on Chinese suppliers for important chemical inputs.

A 2026 analysis by the Information Technology and Innovation Foundation, using US FDA API Drug Master File data, illustrates the changing geography of production. It estimates that China's share of active API filings rose to 45% in 2024, India's to 43%, while Europe's fell to 6% and the United States to 3%. These figures concern the distribution of active API Drug Master File records in that dataset; they are not direct measurements of global API production volume or every medicine's supply chain.

The important point is the structural change.

The changing geography of API supply

Shares of active API Drug Master File records in the cited 2024 dataset

China

45%

India

43%

Europe

6%

United States

3%

Source: ITIF analysis of FDA API Drug Master File data. The displayed figures are rounded. They should not be interpreted as production-volume shares.

This concentration has become a national-security concern.

A May 2026 Council on Geostrategy report argues that US and European antibiotic supply chains are particularly exposed to Chinese upstream ingredients. Its findings highlight how dependence can exist even when the final medicine is manufactured elsewhere.

Council on Geostrategy

The Council on Foreign Relations' October 2026 report similarly examines US and European exposure to Chinese pharmaceutical ingredients and chemical precursors. It identifies the upstream supply chain as an important vulnerability.

Council on Foreign Relations

The lesson is clear:

The country that manufactures the final tablet does not necessarily control the supply chain that makes the tablet possible.

China: From the World's Pharmacy Workshop to a Biotechnology Power?






China's pharmaceutical transformation is one of the most consequential developments in the industry.

For years, China was widely associated with chemical intermediates, pharmaceutical ingredients, generic medicines and large-scale manufacturing.

It is now expanding into more sophisticated areas:

  • Innovative drug discovery.

  • Oncology and immunology.

  • Antibody-based medicines.

  • Cell and gene therapies.

  • Clinical research.

  • Contract research and manufacturing.

  • Biotechnology platforms.

  • Pharmaceutical AI.

This is an important change because it moves China further up the pharmaceutical value chain.

China's emerging biotechnology ecosystem

Companies such as:

  • BeiGene.

  • Innovent Biologics.

  • WuXi Biologics.

  • Hengrui Pharmaceuticals.

  • 3SBio.

illustrate the breadth of China's developing pharmaceutical sector.

The most significant development may be the increasing international interest in Chinese drug candidates.

The OECD's January 2026 biotechnology report describes China's expanding role in global pharmaceutical licensing, clinical trials and biotechnology intellectual property. It notes that Chinese biotechnology companies were involved in 18% of multinational licensing deals by July 2025.

A further indication came in September 2026, when Reuters reported that Chinese biotechnology licensing deals had reached approximately $115 billion globally in 2025. US pharmaceutical companies were among the firms seeking access to Chinese-developed drug candidates. These are reported deal values, which can include milestone payments and contingent future obligations rather than immediate cash payments.

This raises an important question.

If American and European pharmaceutical companies increasingly license promising medicines from Chinese biotechnology companies, could China become an important source of pharmaceutical innovation rather than simply a manufacturing location?

It is a possibility already supported by the expansion of Chinese research and licensing activity.

China's strategic advantages

  • A large domestic healthcare market.

  • Extensive chemical and manufacturing capacity.

  • Growing clinical research infrastructure.

  • Government-supported biotechnology investment.

  • Large pools of scientific and engineering talent.

  • Expanding contract manufacturing capabilities.

China's challenges

  • International trust and regulatory acceptance.

  • Intellectual-property concerns.

  • Geopolitical restrictions.

  • Dependence on some foreign technologies and specialised equipment.

  • The need to demonstrate that promising drug candidates can become safe, commercially successful medicines.

China's progress does not mean it has displaced American or European pharmaceutical leadership.

But it is increasingly difficult to analyse the future of global biotechnology without treating China as a major source of innovation.

The United States: Can It Maintain Leadership in Pharmaceutical Innovation?






The United States has one of the world's deepest pharmaceutical innovation ecosystems.

Its advantages include:

  • Leading research universities.

  • Biotechnology start-ups.

  • Venture capital.

  • Pharmaceutical companies.

  • Clinical trial networks.

  • Advanced medical institutions.

  • Strong intellectual-property and licensing markets.

  • A large and commercially important healthcare market.

Major companies include Pfizer, Merck, Eli Lilly, Johnson & Johnson, AbbVie and Amgen.

The American pharmaceutical model has historically been particularly strong in discovering and commercialising high-value medicines.

However, the industry faces several pressures.

First, drug affordability. High prices create political and public pressure, particularly for medicines with limited competition.

Second, manufacturing dependence. Some essential pharmaceutical ingredients and intermediates are produced abroad.

Third, global competition. Chinese biotechnology companies are becoming more important partners and competitors.

Fourth, research economics. Drug development remains expensive, lengthy and risky. Many promising candidates fail during clinical development.

The United States is responding through investment in domestic manufacturing and efforts to diversify supply chains.

But there is a strategic tension: restricting foreign dependencies while maintaining access to international scientific partnerships.

The September 2026 Reuters report on potential US rules for pharmaceutical licensing and investment involving China illustrates that tension. American drugmakers want access to promising Chinese innovations, while some policymakers are concerned about strategic dependence and biotechnology security.

The American challenge is therefore not simply to manufacture more medicines domestically.

It is to maintain a competitive innovation ecosystem while ensuring reliable access to essential products.

 India: The World's Generic Medicine Powerhouse





India occupies a distinctive position in the global pharmaceutical industry.

It has become one of the world's most important suppliers of generic medicines and vaccines.

Its pharmaceutical industry serves domestic patients and international markets, including the United States, Europe, Africa and other parts of Asia.

Major companies include:

  • Sun Pharmaceutical Industries.

  • Dr. Reddy's Laboratories.

  • Cipla.

  • Lupin.

  • Biocon.

  • Serum Institute of India.

India's importance rests on several factors:

Generic medicine production: When patents expire, Indian manufacturers can produce lower-cost versions of many medicines, subject to regulatory approval.

Vaccine manufacturing: India has substantial capacity to produce vaccines at scale.

Skilled workforce: The country has a large pool of pharmaceutical scientists, chemists, engineers and manufacturing professionals.

Export networks: Indian manufacturers have developed experience supplying regulated international markets.

But India faces a strategic weakness.

It remains heavily dependent on China for important pharmaceutical ingredients.

According to India's Ministry of Chemicals and Fertilizers, in FY2024–25 the country imported approximately $4.35 billion in APIs, bulk drugs and intermediates across 200 categories. China accounted for about 73.7% of these imports.

This creates a contradiction.

India is a major manufacturer of finished medicines, but some of the ingredients needed to produce them come from China.

The challenge for India is to move further upstream into chemical intermediates, APIs, biotechnology and advanced pharmaceutical manufacturing.

India's future pharmaceutical influence may depend on whether it can combine its generic medicine leadership with deeper control over the ingredients and technologies behind those medicines.

Europe: Can Its Pharmaceutical Giants Defend Their Position?






Europe remains one of the world's most important pharmaceutical centres.

Its strengths include research universities, established pharmaceutical companies, advanced manufacturing, biotechnology, regulatory institutions and specialised chemical industries.

Some of its leading companies include:

  • Roche.

  • Novartis.

  • Sanofi.

  • AstraZeneca.

  • Novo Nordisk.

  • Bayer.

Europe has particularly important capabilities in oncology, immunology, vaccines, rare diseases, biologics and pharmaceutical manufacturing.

However, its position is under pressure.

Competition for research investment is intensifying. Some companies are directing more investment towards the United States and China, where large markets, financing and clinical-development opportunities can be attractive.

A 2026 pharmaceutical industry assessment by Atradius identifies regulatory and cost pressures, competition for investment and slower clinical-trial processes among the challenges facing European pharmaceutical producers.

Europe also faces the question of supply-chain resilience.

Its pharmaceutical manufacturing strength does not guarantee independence in every upstream ingredient.

The October 2026 Council on Foreign Relations report on pharmaceutical dependence examines how European manufacturers can remain exposed to Chinese chemical inputs even when medicines are produced within Europe.

Council on Foreign Relations

The European challenge is to preserve its research and manufacturing base while making pharmaceutical production more competitive and supply chains more resilient.

Japan: Precision Chemistry, Advanced Medicines and Pharmaceutical Quality





Japan is an important pharmaceutical economy, although its international role is sometimes less visible than that of the United States or Europe.

Its strengths include:

  • Pharmaceutical research and development.

  • Precision chemical manufacturing.

  • Advanced materials.

  • Quality-control engineering.

  • Biopharmaceutical development.

  • Regenerative medicine.

  • Medical-device integration.

Important companies include Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo and Chugai Pharmaceutical.

Japan has particular strengths in oncology, biologics and specialised therapies.

Daiichi Sankyo, for example, has developed an important international position in antibody-drug conjugates — medicines designed to deliver cancer-fighting substances more selectively to target cells.

Japan is also pursuing regenerative medicine and cell-based therapies, building on its research capabilities in stem cells and tissue engineering.

Its challenges include demographic pressures, competition for global research investment and the need to strengthen its position in some newer biotechnology platforms.

Japan's pharmaceutical future may depend on connecting its traditional strengths in precision chemistry and quality manufacturing with emerging biotechnology and international partnerships.

South Korea: The Biopharmaceutical Manufacturing Challenger





South Korea is becoming increasingly important in biopharmaceutical manufacturing.

Its industrial model draws on strengths in electronics, engineering, manufacturing, automation and international trade.

A major example is Samsung Biologics.

The company operates as a contract development and manufacturing organisation, or CDMO.

This is a significant business model.

Instead of developing and selling every medicine under its own brand, a CDMO manufactures medicines for other pharmaceutical companies.

The business requires advanced facilities, technical expertise, quality systems and the ability to produce complex biological medicines at commercial scale.

Other important companies include Celltrion and SK bioscience.

South Korea's opportunity is to become a major manufacturing and development partner for global biotechnology companies.

Its competitive position will depend on manufacturing reliability, regulatory compliance, production costs, technology and the ability to secure long-term contracts.

The New Battleground: Who Controls Vaccines?



Vaccines occupy a special position in the pharmaceutical industry.

They protect populations against infectious diseases, but they also have strategic importance during pandemics and public-health emergencies.

The COVID-19 pandemic demonstrated that vaccine production capacity is not distributed evenly around the world.

Countries with established biotechnology industries and manufacturing facilities were better positioned to develop, produce or secure supplies.

The global vaccine industry includes several important players:

Country or region

Important capabilities and companies

United States

Pfizer, Moderna, Merck

Europe

Sanofi, GSK, BioNTech

India

Serum Institute of India, Bharat Biotech

China

Sinovac, Sinopharm, CanSino

Japan

Takeda, Daiichi Sankyo

South Korea

SK bioscience, Samsung Biologics

These companies have different product portfolios and manufacturing models. Their presence does not mean they have equal capabilities across every vaccine technology.

The mRNA revolution

One of the most important developments during COVID-19 was the commercialisation of mRNA vaccines.

Unlike traditional vaccines that use weakened or inactivated pathogens, mRNA vaccines provide genetic instructions that help the body produce a target antigen and develop an immune response.

This technology has potential applications beyond COVID-19, including research into cancer vaccines and other infectious diseases.

Companies such as Moderna and BioNTech have invested heavily in mRNA research.

However, mRNA is not a universal solution. Different diseases require different approaches, and vaccine performance, storage, production costs and clinical evidence vary.

Why vaccine manufacturing matters geopolitically

A country with domestic vaccine capacity can improve its ability to respond to outbreaks.

It can also contribute to international supply, regional public-health security and scientific collaboration.

But manufacturing capacity alone is insufficient.

A viable vaccine industry requires:

  • Research and development.

  • Clinical trials.

  • Regulatory approval.

  • Reliable production.

  • Quality assurance.

  • Cold-chain distribution where required.

  • Sustainable purchasing commitments.

The next vaccine competition will therefore be about more than discovering the next breakthrough.

It will be about who can produce it safely, at scale and at a price that allows broad access.

The Patent War: Who Owns the Medicines?

Intellectual property is one of the most powerful forces shaping the pharmaceutical industry.

Developing a new medicine can require years of research, expensive clinical trials, specialist manufacturing and substantial investment.

Patents provide time-limited legal protection for qualifying inventions, helping companies recover research costs and earn returns.

But patents also influence medicine prices and the ability of other manufacturers to enter the market.

This creates a difficult balance.

Without effective incentives, private investment in risky research could decline.

But if essential medicines remain unaffordable because of limited competition or restrictive licensing, patients may be unable to access treatments.

The TRIPS agreement

The World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights, known as TRIPS, establishes international minimum standards for intellectual-property protection.

It also provides flexibilities, including compulsory licensing under specified conditions.

The 2001 Doha Declaration reaffirmed that TRIPS should be interpreted and implemented in a way that supports members' right to protect public health and promote access to medicines.

This remains important for developing countries.

A government facing a serious public-health emergency may need to consider available legal mechanisms to improve access to essential medicines.

But the relationship between patents, innovation and affordability is complex.

The emerging biotechnology licensing contest

China's growing pharmaceutical innovation is adding a new dimension.

American and European companies are increasingly interested in licensing drug candidates from Chinese biotechnology firms.

This creates a two-way relationship:

  • Chinese companies gain access to international capital, expertise and commercial networks.

  • Western companies gain access to promising research and potential medicines.

  • Both sides become commercially interconnected.

The September 2026 Reuters report on US pharmaceutical licensing discussions with Chinese developers illustrates the growing importance of these relationships.

Reuters

The future pharmaceutical industry may therefore be less nationally self-contained than political rhetoric sometimes suggests.

Scientific collaboration and competition can exist simultaneously.

Artificial Intelligence: Is Drug Discovery About to Change?





Drug discovery is traditionally a slow and expensive process.

Researchers must identify a biological target, develop potential compounds, test them, evaluate toxicity, conduct clinical trials and demonstrate that a treatment works.

Many promising candidates fail.

AI could help accelerate selected stages of this process.

Its applications include:

  • Predicting protein structures.

  • Identifying potential drug targets.

  • Designing candidate molecules.

  • Screening chemical compounds.

  • Analysing clinical-trial data.

  • Identifying patient subgroups.

  • Supporting manufacturing quality control.

The work of DeepMind on AlphaFold has demonstrated how AI can advance the prediction of protein structures, providing valuable tools for biological research.

However, predicting a protein structure is not the same as developing an approved medicine.

A candidate still needs laboratory testing, safety assessment, clinical trials and regulatory approval.

The economic opportunity is substantial, but the technology should be viewed as an accelerator of scientific research rather than a replacement for experimental biology.

The companies that combine AI with strong laboratories, clinical networks and manufacturing capabilities may gain an advantage.

This is another reason why pharmaceutical competition increasingly overlaps with the global AI and semiconductor industries.

The Contract Manufacturing Revolution: Who Makes Medicines for Everyone Else?

An important part of the pharmaceutical industry operates behind the brands consumers recognise.

These are contract development and manufacturing organisations — CDMOs.

A pharmaceutical company may discover a drug but decide to outsource some or all of its manufacturing.

A CDMO provides specialised production facilities, technical expertise and regulatory-quality systems.

This can reduce the need for drug developers to build expensive factories themselves.

The business is particularly important for biologics, vaccines and complex injectable medicines.

Companies such as:

  • Samsung Biologics.

  • Lonza.

  • WuXi Biologics.

  • Catalent.

  • Fujifilm Biotechnologies.

illustrate this international manufacturing network.

This creates a different form of pharmaceutical influence.

A country may not own the patents for a medicine, but its factories may be essential to producing it.

The strategic question is whether the world's pharmaceutical industry will become increasingly dependent on a small number of specialised manufacturing hubs.

If so, CDMOs will become even more important to global health security.

Africa: Can the Continent Become a Pharmaceutical Manufacturing Power?

Africa is perhaps the most important test of whether the global pharmaceutical system can become more geographically balanced.

The continent has a large population, substantial healthcare needs and a growing number of pharmaceutical manufacturers.

Yet it remains heavily dependent on imported medicines, vaccines, active pharmaceutical ingredients and medical technologies.

Africa CDC's 2025 annual report describes the scale of the challenge:

  • Africa produces approximately 1% of the vaccines it uses.

  • More than 95% of its pharmaceutical active ingredients are imported.

  • The continent has more than 570 pharmaceutical manufacturers, although many concentrate on formulation and packaging rather than upstream ingredient production.

  • More than 27 vaccine manufacturing initiatives are underway.

  • At least eight vaccine products are expected to reach the market or WHO prequalification by 2030.

These figures demonstrate both the weakness and the potential of the African pharmaceutical industry.

The African Union has established an ambition to meet at least 60% of the continent's health-product needs through local manufacturing by 2040. This is a strategic target, not an achieved production level.

How could Africa move towards that objective?

A. Nigeria: Build on the pharmaceutical manufacturing base

Nigeria has one of Africa's larger pharmaceutical markets and an established domestic manufacturing sector.

Its opportunities include:

  • Generic medicine production.

  • Antimalarial and antibiotic manufacturing.

  • Antiretroviral medicines.

  • Pharmaceutical packaging.

  • Medical consumables.

  • Laboratory reagents.

  • Selected active pharmaceutical ingredients.

Companies such as Fidson Healthcare and Emzor Pharmaceutical Industries illustrate the domestic manufacturing base.

Nigeria could become an important regional pharmaceutical production and distribution centre.

However, its progress will depend on reliable electricity, financing, quality assurance, access to ingredients, regulatory capacity and predictable procurement.

B. South Africa: Advanced pharmaceutical and biotechnology capabilities

South Africa has established pharmaceutical, biotechnology and research capabilities.

Companies such as Aspen Pharmacare have an international manufacturing and distribution presence.

The country has opportunities in:

  • Pharmaceutical formulation.

  • Sterile medicines.

  • Biopharmaceutical manufacturing.

  • Vaccine development and production.

  • Clinical research.

  • Pharmaceutical packaging and distribution.

South Africa's scientific and industrial infrastructure could support partnerships across the continent.

C. Egypt: Pharmaceuticals and regional supply

Egypt has a substantial pharmaceutical manufacturing sector and a large domestic market.

Its geographical position also offers access to African, Middle Eastern and Mediterranean markets.

It could strengthen its role in generic medicines, active ingredients, sterile products and pharmaceutical exports.

D. Morocco, Kenya, Ghana and Ethiopia: Regional specialisation

These countries also have opportunities to strengthen domestic and regional production.

  • Morocco can develop pharmaceutical manufacturing linked to its industrial and export infrastructure.

  • Kenya can expand its pharmaceutical and medical-product manufacturing base.

  • Ghana can build on its pharmaceutical industry and regional trade connections.

  • Ethiopia can strengthen local medicine production and pharmaceutical supply resilience.

The objective should not be for every country to manufacture every medicine.

It should be to build complementary regional capabilities.

The African Pharmaceutical Industrial Strategy: What Should Come First?

Africa needs a realistic industrial sequence.

Attempting to manufacture the world's most advanced cancer therapies before developing reliable essential-medicine production would be economically difficult.

A more practical strategy would involve five stages.

  1. Stage 1 — Essential medicines

    Expand quality-assured production of generic medicines, antibiotics, antimalarials, antiretrovirals and essential injectable products.

  2. Stage 2 — Pharmaceutical ingredients

    Develop selected API and chemical-intermediate production where there is sufficient regional demand and commercial viability.

  3. Stage 3 — Vaccines and biologics

    Build specialised facilities, technical skills, regulatory systems and long-term procurement agreements.

  4. Stage 4 — Research and development

    Expand clinical trials, pharmaceutical research, university-industry partnerships and biotechnology capabilities.

  5. Stage 5 — African-owned innovation

    Develop proprietary medicines, biotechnology platforms, manufacturing processes and intellectual property.

The industrial strategy must also address four essential requirements.

1. Regional demand

A pharmaceutical factory needs reliable customers. Individual national markets may be too small to support some expensive manufacturing facilities.

Regional procurement and pooled purchasing could create more predictable demand.

2. Regulatory harmonisation

Medicines must meet consistent safety and quality standards. The African Medicines Agency can play an important role in improving regulatory coordination.

3. Financing

Pharmaceutical facilities require long-term capital, technical expertise and strict quality systems. Commercial banks alone may not finance all strategic investments.

Development banks, pension funds, industrial investors and international partners could contribute through carefully structured financing.

4. Guaranteed procurement

Local manufacturers need dependable orders.

Governments and international health organisations should consider predictable purchasing commitments where locally produced medicines meet required standards and offer competitive value.

Without demand, factories risk becoming expensive buildings with insufficient production.

Africa–Asia Partnerships: Can a New Pharmaceutical Industrial Corridor Emerge?

Africa's pharmaceutical future could be shaped significantly by partnerships with Asia.

Different countries have capabilities that could complement African industrial development.

Partner

Potential contribution to African pharmaceutical development

China

Chemical intermediates, APIs, manufacturing equipment and production technology

India

Generic medicines, pharmaceutical training, formulation and technology transfer

Japan

Precision equipment, quality control, advanced materials and pharmaceutical engineering

South Korea

Biopharmaceutical manufacturing, vaccines and CDMO expertise

Taiwan

Medical electronics, laboratory equipment and precision components

Europe

Regulatory systems, pharmaceutical research and advanced manufacturing

United States

Biotechnology, clinical research, AI drug discovery and investment

India could be particularly important because its experience in generic medicine production is relevant to African markets.

China could contribute manufacturing equipment, chemical inputs and industrial infrastructure.

Japan and South Korea could support advanced manufacturing, automation and quality-control capabilities.

Taiwan's electronics industry could help develop laboratory instruments, diagnostic devices and connected pharmaceutical manufacturing systems.

But Africa must negotiate carefully.

A partnership should not be judged solely by the number of factories announced or the value of imported equipment.

It should be evaluated by measurable outcomes:

  • How much is manufactured locally?

  • How much technology is transferred?

  • How many African engineers and scientists are trained?

  • How much local value is added?

  • Are African companies gaining access to intellectual property?

  • Can facilities operate independently over time?

  • Can the products compete in regional and international markets?

The ultimate goal should be to develop African industrial capabilities, not simply expand the sales of foreign pharmaceutical companies.

The Pharmaceutical War and Global Geopolitics

The pharmaceutical industry is increasingly connected to the wider contest over strategic supply chains.

Three developments deserve particular attention.

The United States–China biotechnology relationship

American companies want access to promising Chinese drug candidates, research capabilities and manufacturing partners.

At the same time, policymakers in both countries are concerned about strategic dependence, technology security and control over sensitive biological information.

The September 2026 Reuters report on US pharmaceutical licensing arrangements involving China illustrates this complex relationship.

The relationship is neither complete separation nor unrestricted cooperation.

It is a mixture of commercial interdependence, scientific competition and national-security concerns.

India's pharmaceutical independence challenge

India is a major supplier of finished generic medicines, but its dependence on Chinese pharmaceutical ingredients remains significant.

Its industrial policy therefore has to address both finished products and upstream chemical production.

The question is whether India can become more self-reliant without losing the cost competitiveness that made its pharmaceutical industry internationally successful.

Europe's and America's supply-chain diversification

Western governments are examining how to reduce exposure to concentrated pharmaceutical supply chains.

But rebuilding manufacturing capacity is expensive.

Factories require skilled workers, regulatory approvals, reliable energy, environmental controls and long-term purchasing commitments.

Simply relocating production does not guarantee lower costs or a more resilient supply chain.

A more realistic strategy may involve several trusted manufacturing locations rather than attempting complete national self-sufficiency.

Who Could Control the Pharmaceutical Industry by 2035?

The future will not necessarily belong to one country.

Different economies may control different parts of the pharmaceutical value chain.

The emerging pharmaceutical power structure


United States

Biotechnology innovation, pharmaceutical research, venture capital and advanced therapeutics.


China

Chemical intermediates, APIs, expanding biotechnology research and manufacturing scale.


India

Generic medicines, vaccines and pharmaceutical exports.


Europe

Established pharmaceutical research, biologics, specialised medicines and manufacturing.


Japan

Advanced medicines, precision chemistry, specialised treatments and quality manufacturing.


South Korea

Biopharmaceutical manufacturing and contract production.


Africa

Emerging regional production of essential medicines, vaccines, diagnostics and medical products.

These are areas of existing capability and strategic opportunity, not predictions that each region will dominate its respective category by 2035.

The industry is likely to remain internationally interconnected.

A cancer medicine could involve research in America, a biological component developed in China, contract manufacturing in South Korea, specialised equipment from Japan and final distribution through European and African pharmaceutical networks.

The future may therefore be determined by networks of companies and countries rather than isolated national champions.

Three Possible Futures for the Global Pharmaceutical Industry

Future A — A More Distributed Pharmaceutical Economy

More countries develop manufacturing capacity, international partnerships diversify supply chains, and competition improves access to essential medicines.


Future B — Concentrated Biotechnology Power

A relatively small number of economies control advanced drug discovery, biotechnology platforms, intellectual property and specialised manufacturing. Other countries remain dependent on imported products.


Future C — Fragmented Pharmaceutical Blocs

Geopolitical tensions encourage competing supply chains, duplicated factories, trade restrictions and different regulatory systems. Some countries gain resilience, but production costs and market fragmentation may increase.

The three scenarios could coexist in different parts of the industry.

For example, generic medicine production might become more geographically distributed while advanced cell and gene therapies remain concentrated in a relatively small number of countries.

Final Assessment: The Future of Medicine Is Also a Question of Industrial Power

The pharmaceutical industry is undergoing a fundamental transformation.

The old model — in which a relatively small number of established pharmaceutical companies developed medicines and supplied international markets — is being challenged by new biotechnology firms, AI-driven research, manufacturing competition and changing geopolitical relationships.

China is expanding from pharmaceutical manufacturing into more sophisticated biotechnology.

India remains a major force in generic medicines and vaccine production, while seeking greater control over upstream ingredients.

The United States retains substantial pharmaceutical research and biotechnology capabilities.

Europe continues to possess major pharmaceutical companies and manufacturing expertise.

Japan brings precision chemistry and specialised pharmaceutical research.

South Korea is building a significant position in biopharmaceutical manufacturing.

Africa is beginning to develop a more ambitious regional pharmaceutical manufacturing agenda.

But one distinction must remain clear: manufacturing medicines is not the same as discovering them, and discovering medicines is not the same as making them affordable.

A country may possess one capability without possessing the others.

The countries that develop strong pharmaceutical ecosystems will need to connect scientific research, intellectual property, manufacturing, regulatory quality, financing and distribution.

For Africa, the opportunity is particularly important.

The continent should not measure success only by how many pharmaceutical factories it builds. It should measure success by the quality of the medicines produced, the ingredients manufactured locally, the technologies transferred, the scientists trained and the number of people who gain reliable access to affordable treatment.

The African Union's 60% local health-product manufacturing ambition by 2040 provides a direction. Turning it into reality will require sustained investment, regional markets, predictable procurement and industrial discipline.

Ultimately, the global pharmaceutical war should not be reduced to a contest over which country earns the most money or controls the largest market.

Medicines are not ordinary consumer products. Their availability affects life expectancy, national resilience, economic productivity and human security.

The most consequential pharmaceutical power of the 21st century may belong to those who can combine innovation with manufacturing capacity — and make the resulting medicines accessible to the greatest number of people.

The ultimate question is not simply who owns the medicines of the future.

It is whether humanity can build a pharmaceutical system in which the benefits of scientific progress are not reserved for the countries and populations that can pay the most.

By Jugo Ikeji Uju

Content Sponsorship available-

With links on ubuntusafa.com

Contact admin:

sappertekinc@gmail.com

admin@ubuntusafa.com

No comments:

Post a Comment

New Posts

TERAFAB FUTURE — TECHNOLOGY:- Can Terafab manufacture competitive chips at advanced process nodes, rather than merely design them?

  TERAFAB FUTURE — TECHNOLOGY   Can Terafab manufacture competitive chips at advanced process nodes, rather than merely design them? The cen...

Recent Post